These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 34588193)

  • 1. Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension.
    Toshner M; Church C; Harbaum L; Rhodes C; Villar Moreschi SS; Liley J; Jones R; Arora A; Batai K; Desai AA; Coghlan JG; Gibbs JSR; Gor D; Gräf S; Harlow L; Hernandez-Sanchez J; Howard LS; Humbert M; Karnes J; Kiely DG; Kittles R; Knightbridge E; Lam B; Lutz KA; Nichols WC; Pauciulo MW; Pepke-Zaba J; Suntharalingam J; Soubrier F; Trembath RC; Schwantes-An TL; Wort SJ; Wilkins MR; Gaine S; Morrell NW; Corris PA;
    Eur Respir J; 2022 Mar; 59(3):. PubMed ID: 34588193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis.
    ; Swerdlow DI; Holmes MV; Kuchenbaecker KB; Engmann JE; Shah T; Sofat R; Guo Y; Chung C; Peasey A; Pfister R; Mooijaart SP; Ireland HA; Leusink M; Langenberg C; Li KW; Palmen J; Howard P; Cooper JA; Drenos F; Hardy J; Nalls MA; Li YR; Lowe G; Stewart M; Bielinski SJ; Peto J; Timpson NJ; Gallacher J; Dunlop M; Houlston R; Tomlinson I; Tzoulaki I; Luan J; Boer JM; Forouhi NG; Onland-Moret NC; van der Schouw YT; Schnabel RB; Hubacek JA; Kubinova R; Baceviciene M; Tamosiunas A; Pajak A; Topor-Madry R; Malyutina S; Baldassarre D; Sennblad B; Tremoli E; de Faire U; Ferrucci L; Bandenelli S; Tanaka T; Meschia JF; Singleton A; Navis G; Mateo Leach I; Bakker SJ; Gansevoort RT; Ford I; Epstein SE; Burnett MS; Devaney JM; Jukema JW; Westendorp RG; Jan de Borst G; van der Graaf Y; de Jong PA; Mailand-van der Zee AH; Klungel OH; de Boer A; Doevendans PA; Stephens JW; Eaton CB; Robinson JG; Manson JE; Fowkes FG; Frayling TM; Price JF; Whincup PH; Morris RW; Lawlor DA; Smith GD; Ben-Shlomo Y; Redline S; Lange LA; Kumari M; Wareham NJ; Verschuren WM; Benjamin EJ; Whittaker JC; Hamsten A; Dudbridge F; Delaney JA; Wong A; Kuh D; Hardy R; Castillo BA; Connolly JJ; van der Harst P; Brunner EJ; Marmot MG; Wassel CL; Humphries SE; Talmud PJ; Kivimaki M; Asselbergs FW; Voevoda M; Bobak M; Pikhart H; Wilson JG; Hakonarson H; Reiner AP; Keating BJ; Sattar N; Hingorani AD; Casas JP
    Lancet; 2012 Mar; 379(9822):1214-24. PubMed ID: 22421340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma markers in pulmonary hypertension subgroups correlate with patient survival.
    Koudstaal T; van Uden D; van Hulst JAC; Heukels P; Bergen IM; Geenen LW; Baggen VJM; van den Bosch AE; van den Toorn LM; Chandoesing PP; Kool M; Boersma E; Hendriks RW; Boomars KA
    Respir Res; 2021 May; 22(1):137. PubMed ID: 33947407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical trial protocol for TRANSFORM-UK: A therapeutic open-label study of tocilizumab in the treatment of pulmonary arterial hypertension.
    Hernández-Sánchez J; Harlow L; Church C; Gaine S; Knightbridge E; Bunclark K; Gor D; Bedding A; Morrell N; Corris P; Toshner M
    Pulm Circ; 2018; 8(1):2045893217735820. PubMed ID: 28956500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selonsertib in adults with pulmonary arterial hypertension (ARROW): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Rosenkranz S; Feldman J; McLaughlin VV; Rischard F; Lange TJ; White RJ; Peacock AJ; Gerhardt F; Ebrahimi R; Brooks G; Satler C; Frantz RP;
    Lancet Respir Med; 2022 Jan; 10(1):35-46. PubMed ID: 34425071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Mutations and Decreased Expression of the Epigenetic Regulator
    Potus F; Pauciulo MW; Cook EK; Zhu N; Hsieh A; Welch CL; Shen Y; Tian L; Lima P; Mewburn J; D'Arsigny CL; Lutz KA; Coleman AW; Damico R; Snetsinger B; Martin AY; Hassoun PM; Nichols WC; Chung WK; Rauh MJ; Archer SL
    Circulation; 2020 Jun; 141(24):1986-2000. PubMed ID: 32192357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial.
    Hoeper MM; Al-Hiti H; Benza RL; Chang SA; Corris PA; Gibbs JSR; Grünig E; Jansa P; Klinger JR; Langleben D; McLaughlin VV; Meyer GMB; Ota-Arakaki J; Peacock AJ; Pulido T; Rosenkranz S; Vizza CD; Vonk-Noordegraaf A; White RJ; Chang M; Kleinjung F; Meier C; Paraschin K; Ghofrani HA; Simonneau G;
    Lancet Respir Med; 2021 Jun; 9(6):573-584. PubMed ID: 33773120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytokines, Chemokines, and Inflammation in Pulmonary Arterial Hypertension.
    Liang S; Desai AA; Black SM; Tang H
    Adv Exp Med Biol; 2021; 1303():275-303. PubMed ID: 33788198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multi-biobank summary data Mendelian randomisation does not support a causal effect of IL-6 signalling on risk of pulmonary arterial hypertension.
    Woolf B; Perry JA; Hong CC; Wilkins MR; Toshner M; Gill D; Burgess S; Rhodes CJ
    Eur Respir J; 2024 Apr; 63(4):. PubMed ID: 38453257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Risk factors for death and the clinical features of different subtypes of patients with pulmonary arterial hypertension related to congenital heart disease].
    Xu ZY; Li QQ; Zhang C; Zhang HS; Gu H
    Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Apr; 48(4):315-322. PubMed ID: 32370483
    [No Abstract]   [Full Text] [Related]  

  • 11. Adverse Events in Connective Tissue Disease-Associated Pulmonary Arterial Hypertension.
    Rhee RL; Gabler NB; Praestgaard A; Merkel PA; Kawut SM
    Arthritis Rheumatol; 2015 Sep; 67(9):2457-65. PubMed ID: 26016953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Right Atrial Conduit Phase Emptying Predicts Risk of Adverse Events in Pediatric Pulmonary Arterial Hypertension.
    Frank BS; Schafer M; Thomas TM; Haxel C; Ivy DD; Jone PN
    J Am Soc Echocardiogr; 2020 Aug; 33(8):1006-1013. PubMed ID: 32336608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel therapeutic approach in pulmonary arterial hypertension as a complication of adult-onset Still's disease: targeting IL-6.
    Kadavath S; Zapantis E; Zolty R; Efthimiou P
    Int J Rheum Dis; 2014 Mar; 17(3):336-40. PubMed ID: 24581387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
    Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
    Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FUTURE-2: Results from an open-label, long-term safety and tolerability extension study using the pediatric FormUlation of bosenTan in pUlmonary arterial hypeRtEnsion.
    Berger RM; Haworth SG; Bonnet D; Dulac Y; Fraisse A; Galiè N; Ivy DD; Jaïs X; Miera O; Rosenzweig EB; Efficace M; Kusic-Pajic A; Beghetti M
    Int J Cardiol; 2016 Jan; 202():52-8. PubMed ID: 26386921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current epoprostenol use in patients with severe idiopathic, heritable or anorexigen-associated pulmonary arterial hypertension: data from the French pulmonary hypertension registry.
    Bergot E; Sitbon O; Cottin V; Prévot G; Canuet M; Bourdin A; de Groote P; Rottat L; Gressin V; Jaïs X; Humbert M; Simonneau G
    Int J Cardiol; 2014 Apr; 172(3):561-7. PubMed ID: 24529947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in REVEAL risk score in patients with pulmonary arterial hypertension treated with macitentan in clinical practice: results from the PRACMA study.
    Escribano-Subias P; López R; Almenar L; Lázaro M; Forn I; Torrent A; Blanco I; Barberà JA;
    BMC Pulm Med; 2020 Jun; 20(1):154. PubMed ID: 32487059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tadalafil in idiopathic or heritable pulmonary arterial hypertension (PAH) compared to PAH associated with connective tissue disease.
    Galiè N; Denton CP; Dardi F; Manes A; Mazzanti G; Li B; Varanese L; Esler A; Harmon C; Palazzini M
    Int J Cardiol; 2017 May; 235():67-72. PubMed ID: 28279499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular sources of interleukin-6 and associations with clinical phenotypes and outcomes in pulmonary arterial hypertension.
    Simpson CE; Chen JY; Damico RL; Hassoun PM; Martin LJ; Yang J; Nies M; Griffiths M; Vaidya RD; Brandal S; Pauciulo MW; Lutz KA; Coleman AW; Austin ED; Ivy DD; Nichols WC; Everett AD
    Eur Respir J; 2020 Apr; 55(4):. PubMed ID: 32029443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated Interleukin-6 Levels Predict Clinical Worsening in Pediatric Pulmonary Arterial Hypertension.
    Chen JY; Griffiths M; Yang J; Nies MK; Damico RL; Simpson CE; Vaidya RD; Brandal S; Ivy DD; Austin ED; Nichols WC; Pauciulo MW; Lutz K; Rosenzweig EB; Hirsch R; Yung D; Everett AD
    J Pediatr; 2020 Aug; 223():164-169.e1. PubMed ID: 32711743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.